Referencias:
3 December Risk Assessment for SARS-CoV-2 variant: Omicron VOC-21Nov (b1.1.529); https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1038442/3_December-2021-risk-assessment-for-SARS_Omicron_VOC-21NOV-01_B.1.1.529.pdf
Commissioner, O. O. (n.d.). Coronavirus (COVID-19) Update: FDA Actively Working to Investigate, Address Potential Impacts of Omicron Variant; Urges Vaccination and Boosters. Retrieved from https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-actively-working-investigate-address-potential-impacts-omicron
National Institute for Communicable Diseases; https://www.nicd.ac.za
Pulliam, J. R., van Schalkwyk, C., Govender, N., von Gottberg, A., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021). Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. MedXRiv.Org. Published. https://doi.org/10.1101/2021.11.11.21266068
